Hop bitter acids exhibit anti-fibrogenic effects on hepatic stellate cells in vitro

Experimental and Molecular Pathology

Volumn 92, Issue 2, 2012, Pages 222-228

  Saugspier, Michael ^a   Dorn, Christoph ^a   Thasler, Wolfgang E ^b   Gehrig, Manfred ^c   Heilmann, Jörg ^d   Hellerbrand, Claus ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Nateco ^*  (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Bitter acids; Hepatic fibrosis; Hepatic stellate cells; Hop; Nuclear factor kappa B

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BITTER ACID; COLLAGEN TYPE 1; HERBACEOUS AGENT; HUMULUS LUPULUS EXTRACT; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIFIBROGENIC ACTIVITY; ARTICLE; CELL ISOLATION; CELL NUCLEUS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ISOLATION; DRUG MECHANISM; DRUG TARGETING; GENE; GENE CONTROL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMULUS LUPULUS; IN VITRO STUDY; INFLAMMATION; LIVER FIBROSIS; MCP 1 GENE; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RANTES GENE; SIGNAL TRANSDUCTION; STELLATE CELL; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

ACIDS; ACTINS; ANIMALS; BIOLOGICAL TRANSPORT; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOKINE CCL5; COLLAGEN TYPE I; FEMALE; GENE EXPRESSION REGULATION; HEPATIC STELLATE CELLS; HUMANS; HUMULUS; I-KAPPA B PROTEINS; INFLAMMATION; MICE; MICE, INBRED BALB C; NF-KAPPA B; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

HUMULUS; HUMULUS LUPULUS; MURINAE;

EID: 84857247897     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2011.11.005     Document Type: Article

References (35)

1. Arthur M.J., Iredale J.P., Mann D.A. Tissue inhibitors of metalloproteinases: role in liver fibrosis and alcoholic liver disease. Alcoholism, Clinical and Experimental Research 1999, 23:940-943.
2. Atzori L., Poli G., Perra A. Hepatic stellate cell: a star cell in the liver. The International Journal of Biochemistry & Cell Biology 2009, 41:1639-1642.
3. Bataller R., Brenner D.A. Hepatic stellate cells as a target for the treatment of liver fibrosis. Seminars in Liver Disease 2001, 21:437-451.
4. Bataller R., Brenner D.A. Liver fibrosis. The Journal of Clinical Investigation 2005, 115:209-218.
5. Bosserhoff A.K., Moser M., Scholmerich J., Buettner R., Hellerbrand C. Specific expression and regulation of the new melanoma inhibitory activity-related gene Mia2 in hepatocytes. Journal of Biological Chemistry 2003, 278:15225-15231.
6. Caldwell S.H., Oelsner D.H., Iezzoni J.C., Hespenheide E.E., Battle E.H., Driscoll C.J. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999, 29:664-669.
7. Desai A., Konda V.R., Darland G., Austin M., Prabhu K.S., Bland J.S., Carroll B.J., Tripp M.L. Meta060 inhibits multiple kinases in the Nf-Kappab pathway and suppresses LPS-mediated inflammation in vitro and ex vivo. Inflammation Research 2009, 58:229-234.
8. Dorn C., Kraus B., Motyl M., Weiss T.S., Gehrig M., Scholmerich J., Heilmann J., Hellerbrand C. Xanthohumol, a chalcon derived from hops, inhibits hepatic inflammation and fibrosis. Molecular Nutrition & Food Research 2010.
9. Elsharkawy A.M., Oakley F., Mann D.A. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 2005, 10:927-939.
10. Farber S.M., Masten J.M., Anderson H.H., Gentry R.W., Chin Y.C. Tolerance and effects of lupulon in man. Diseases of the Chest 1950, 18:10-15.
11. Foster B.C., Kearns N., Arnason J.T., Saleem A., Ogrodowczyk C., Desjardins S. Comparative study of hop-containing products on human cytochrome P450-mediated metabolism. Journal of Agricultural and Food Chemistry 2009, 57:5100-5105.
12. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669.
13. Hellerbrand C., Jobin C., Iimuro Y., Licato L., Sartor R.B., Brenner D.A. Inhibition of Nfkappab in activated rat hepatic stellate cells by proteasome inhibitors and an Ikappab super-repressor. Hepatology 1998, 27:1285-1295.
14. Hellerbrand C., Jobin C., Licato L.L., Sartor R.B., Brenner D.A. Cytokines induce Nf-Kappab in activated but not in quiescent rat hepatic stellate cells. American Journal of Physiology 1998, 275:G269-G278.
15. Jarrar M.H., Baranova A., Collantes R., Ranard B., Stepanova M., Bennett C., Fang Y., Elariny H., Goodman Z., Chandhoke V., Younossi Z.M. Adipokines and cytokines in non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics 2008, 27:412-421.
16. Kritchevsky D., Martak D.S., Rothblat G.H. Detection of bile acids in thin-layer chromatography. Analytical Biochemistry 1963, 5:388-392.
17. Lamy V., Roussi S., Chaabi M., Gosse F., Schall N., Lobstein A., Raul F. Chemopreventive effects of lupulone, a hop {beta}-acid, on human colon cancer-derived metastatic Sw620 cells and in a rat model of colon carcinogenesis. Carcinogenesis 2007, 28:1575-1581.
18. Lang A., Schoonhoven R., Tuvia S., Brenner D.A., Rippe R.A. Nuclear factor Kappab in proliferation, activation, and apoptosis in rat hepatic stellate cells. Journal of Hepatology 2000, 33:49-58.
19. Lee K.S., Buck M., Houglum K., Chojkier M. Activation of hepatic stellate cells by Tgf alpha and collagen type I is mediated by oxidative stress through C-Myb expression. The Journal of Clinical Investigation 1995, 96:2461-2468.
20. Lee J.C., Kundu J.K., Hwang D.M., Na H.K., Surh Y.J. Humulone inhibits phorbol ester-induced Cox-2 expression in mouse skin by blocking activation of Nf-Kappab and Ap-1: Ikappab kinase and C-Jun-N-terminal kinase as respective potential upstream targets. Carcinogenesis 2007, 28:1491-1498.
21. Mann J., Mann D.A. Transcriptional regulation of hepatic stellate cells. Advanced Drug Delivery Reviews 2009, 61:497-512.
22. Mann J., Oakley F., Akiboye F., Elsharkawy A., Thorne A.W., Mann D.A. Regulation of myofibroblast transdifferentiation by DNA methylation and Mecp2: implications for wound healing and fibrogenesis. Cell Death and Differentiation 2007, 14:275-285.
23. Miura Y., Hosono M., Oyamada C., Odai H., Oikawa S., Kondo K. Dietary isohumulones, the bitter components of beer, raise plasma hdl-cholesterol levels and reduce liver cholesterol and triacylglycerol contents similar to PPARalpha activations in C57bl/6 mice. British Journal of Nutrition 2005, 93:559-567.
24. Muhlbauer M., Bosserhoff A.K., Hartmann A., Thasler W.E., Weiss T.S., Herfarth H., Lock G., Scholmerich J., Hellerbrand C. A novel Mcp-1 gene polymorphism is associated with hepatic Mcp-1 expression and severity of Hcv-related liver disease. Gastroenterology 2003, 125:1085-1093.
25. Muhlbauer M., Allard B., Bosserhoff A.K., Kiessling S., Herfarth H., Rogler G., Scholmerich J., Jobin C., Hellerbrand C. Differential effects of deoxycholic acid and taurodeoxycholic acid on Nf-Kappa B signal transduction and Il-8 gene expression in colonic epithelial cells. American Journal of Physiology - Gastrointestinal and Liver Physiology 2004, 286:G1000-G1008.
26. Powell E.E., Cooksley W.G., Hanson R., Searle J., Halliday J.W., Powell L.W. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21years. Hepatology 1990, 11:74-80.
27. Shimamura M., Hazato T., Ashino H., Yamamoto Y., Iwasaki E., Tobe H., Yamamoto K., Yamamoto S. Inhibition of angiogenesis by humulone, a bitter acid from beer hop. Biochemical and Biophysical Research Communications 2001, 289:220-224.
28. Steiling H., Muhlbauer M., Bataille F., Scholmerich J., Werner S., Hellerbrand C. Activated hepatic stellate cells express keratinocyte growth factor in chronic liver disease. American Journal of Pathology 2004, 165:1233-1241.
29. Thasler W.E., Weiss T.S., Schillhorn K., Stoll P.T., Irrgang B., Jauch K.W. Charitable state-controlled foundation human tissue and cell research: ethic and legal aspects in the supply of surgically removed human tissue for research in the academic and commercial sector in Germany. Cell and Tissue Banking 2003, 4:49-56.
30. Tobe H., Kubota M., Yamaguchi M., Kocha T., Aoyagi T. Apoptosis to Hl-60 by humulone. Bioscience, Biotechnology, and Biochemistry 1997, 61:1027-1029.
31. Van C.M., Cattoor K., De B.K., Haegeman G., De K.D., Heyerick A. Hop (Humulus lupulus)-derived bitter acids as multipotent bioactive compounds. Journal of Natural Products 2009, 72:1220-1230.
32. Van C.M., Heyerick A., Libert C., Swerts K., Philippe J., De K.D., Haegeman G., De B.K. Hop bitter acids efficiently block inflammation independent of gralpha, PPARalpha, or PPARgamma. Molecular Nutrition & Food Research 2009, 53:1143-1155.
33. Wouters K., Van Gorp P.J., Bieghs V., Gijbels M.J., Duimel H., Lutjohann D., Kerksiek A., Van K.R., Maeda N., Staels B., Van B.M., Shiri-Sverdlov R., Hofker M.H. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008, 48:474-486.
34. Yajima H., Ikeshima E., Shiraki M., Kanaya T., Fujiwara D., Odai H., Tsuboyama-Kasaoka N., Ezaki O., Oikawa S., Kondo K. Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance. Journal of Biological Chemistry 2004, 279:33456-33462.
35. Yajima H., Noguchi T., Ikeshima E., Shiraki M., Kanaya T., Tsuboyama-Kasaoka N., Ezaki O., Oikawa S., Kondo K. Prevention of diet-induced obesity by dietary isomerized hop extract containing isohumulones, in rodents. International Journal of Obesity 2005, 29:991-997.